@article{87b5c17a1c5141cf90299df7ede25d35,
title = "Measurable Residual Disease Detection in B-Acute Lymphoblastic Leukemia: The Children's Oncology Group (COG) Method",
abstract = "Measurable (minimal) residual disease (MRD) in B-acute lymphoblastic leukemia (B-ALL), as assessed by flow cytometry, is an established prognostic factor used to adjust treatment in most pediatric therapeutic protocols. MRD in B-ALL has been standardized by the Children's Oncology Group in North America and more recently in a multicenter Foundation for the National Institutes of Health–funded study. This article outlines the reagents, instrument setup, and analysis protocols required for the reproducible detection of residual leukemic cells in patients following induction therapy for B-ALL.",
keywords = "B-acute lymphoblastic leukemia, Children's Oncology Group, MRD, acute leukemia, flow cytometry, standardization",
author = "Borowitz, {Michael J.} and Wood, {Brent L.} and Michael Keeney and Hedley, {Benjamin D.}",
note = "Funding Information: The standardization project that helped distribute the COG protocol was supported scientifically and financially through the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium project, Grant Title “Minimal Residual Disease (MRD) Detection in Adult Acute Lymphoblastic Leukemia (ALL),” and was made possible through funding support provided to the FNIH by AbbVie Inc., Amgen Inc., Pfizer Inc., and Genentech Inc. In‐kind donations to support flow cytometric assays are being provided to the FNIH by BD Biosciences and Beckman Coulter Inc. Funding Information: The standardization project that helped distribute the COG protocol was supported scientifically and financially through the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium project, Grant Title ?Minimal Residual Disease (MRD) Detection in Adult Acute Lymphoblastic Leukemia (ALL),? and was made possible through funding support provided to the FNIH by AbbVie Inc., Amgen Inc., Pfizer Inc., and Genentech Inc. In-kind donations to support flow cytometric assays are being provided to the FNIH by BD Biosciences and Beckman Coulter Inc. Publisher Copyright: {\textcopyright} 2022 Wiley Periodicals LLC.",
year = "2022",
month = mar,
doi = "10.1002/cpz1.383",
language = "English (US)",
volume = "2",
journal = "Current Protocols",
issn = "2691-1299",
publisher = "John Wiley & Sons Inc.",
number = "3",
}